ResearcherTokyo Metropolitan Komagome HospitalNo recent work listed
Yasuji Seyama
Matched on ORCID iD 0000-0001-9295-495X; OpenAlex author ID A5069794075. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 5
- The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12624↗
- Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
- Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
- [Multidisciplinary Treatment Aids Long-Term Stage Ⅳ Pancreatic Cancer Survival-A Case Report]. Last author PMID 33468777↗
- Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer Using the "Caudo-Dorsal Artery First Approach". First author DOI 10.1245/s10434-019-07789-8↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yusuke Ome · 2 shared papers, 2019–2023 · strength 0.32
- Paper The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreat… DOI 10.1002/ags3.12624↗
- Paper Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer Using the "Caudo-Dorsal Artery First Approach". DOI 10.1245/s10434-019-07789-8↗
- Sara Hayakawa · 2 shared papers, 2020–2023 · strength 0.30
- Masaru Matsumura · 2 shared papers, 2020–2023 · strength 0.30
- Goro Honda · 2 shared papers, 2021–2023 · strength 0.28
- Paper The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreat… DOI 10.1002/ags3.12624↗
- Paper Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cance… DOI 10.1097/mpa.0000000000001702↗
- Masataka Kikuyama · 1 shared paper, 2023 · strength 0.18
- Jun Muto · 1 shared paper, 2019 · strength 0.14
- Shinya Sakamoto · 1 shared paper, 2020 · strength 0.12
- Yuzo Yamamoto · 1 shared paper, 2022 · strength 0.11
- Masakazu Yamamoto · 1 shared paper, 2022 · strength 0.11
- Yuki Homma · 1 shared paper, 2022 · strength 0.11
- Yoshifumi Morita · 1 shared paper, 2022 · strength 0.11
- Kazuhiro Yoshida · 1 shared paper, 2022 · strength 0.11
- Shugo Mizuno · 1 shared paper, 2022 · strength 0.11
- Masayuki Sho · 1 shared paper, 2022 · strength 0.11
- Hiroki Yamaue · 1 shared paper, 2022 · strength 0.11
- Yutaka Takeda · 1 shared paper, 2022 · strength 0.11
- Yuko Mataki · 1 shared paper, 2022 · strength 0.11
- Masaji Tani · 1 shared paper, 2022 · strength 0.11
- Satoshi Hirano · 1 shared paper, 2022 · strength 0.11
- Toshiki Rikiyama · 1 shared paper, 2022 · strength 0.11
- Hideo Baba · 1 shared paper, 2022 · strength 0.11
- Itaru Endo · 1 shared paper, 2022 · strength 0.11
- Akira Fukutomi · 1 shared paper, 2021 · strength 0.10
- Shoji Nakamori · 1 shared paper, 2021 · strength 0.10
- Tatsuyuki Takadate · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.